The Basophil Activation Test Is Not a Useful Screening Tool for Hymenoptera Venom-Related Anaphylaxis in Patients with Systemic Mastocytosis by Rietveld, M.J.A. (Mark J.A.) et al.
E-Mail karger@karger.com
 Original Paper 
 Int Arch Allergy Immunol 2016;169:125–129 
 DOI: 10.1159/000444996 
 The Basophil Activation Test Is Not a Useful 
Screening Tool for Hymenoptera Venom-Related
Anaphylaxis in Patients with Systemic Mastocytosis 
 Mark J.A. Rietveld a    Marco W.J. Schreurs c    Roy Gerth van Wijk b    
Paul L.A. van Daele a, b    Maud A.W. Hermans a, b  
 Sections of  a  Clinical Immunology and  b  Allergy, Department of Internal Medicine, and  c  Department of 
Immunology, Erasmus University Medical Center,  Rotterdam , The Netherlands 
with skin lesions, those without skin lesions had significantly 
more anaphylaxis and sIgE to Hymenoptera. During a 3-year 
follow-up, no one experienced new anaphylactic episodes. 
 Conclusion: The BAT is not a reliable tool for randomly 
screening SM patients for HVA.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Systemic mastocytosis (SM) is a rare disease character-
ized by the proliferation of aberrant mast cells in which at 
least one extracutaneous organ is affected  [1] . Since mast 
cells are the culprit cells of type I hypersensitivity reac-
tions, SM patients are at a high risk for anaphylaxis, with 
a cumulative incidence ranging between 20 and 49%  [2–
4] . Another study showed that 12% of the patients of a 
cohort had life-threatening anaphylaxis, sometimes with 
serious cerebral hypoxic damage  [5] . Patients with skin 
lesions have a lower lifetime risk of anaphylaxis than pa-
tients without skin lesions  [6] . Many triggers can cause 
anaphylactic reactions, but most cases of SM are Hyme-
noptera venom related  [5] . This can obviously lead to life-
threatening situations. Therefore, it would be of great val-
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 Abstract 
 Background: Systemic mastocytosis (SM) patients are at a 
high risk for anaphylaxis, with Hymenoptera as the main cul-
prit. A screening instrument to identify which patients are 
sensitized to Hymenoptera before they experience anaphy-
laxis would therefore be of great value. The basophil activa-
tion test (BAT) is proposed as a possible tool for diagnosing 
Hymenoptera venom-related allergy (HVA), especially in pa-
tients in whom conventional allergy tests yield contradictory 
results.  Methods: We included outpatients with SM, accord-
ing to WHO criteria, from September 2011 to January 2012. 
Next, to obtain various clinical data including intradermal 
test results, specific immunoglobulin E (sIgE) measurements 
and BAT were performed.  Results: We included 29 patients, 
9 of whom had a history of HVA and 4 of whom had experi-
enced anaphylaxis due to other triggers. Sixteen patients 
had no history of anaphylaxis. sIgE was detected in 6 patients 
with HVA and in 2 patients with anaphylaxis due to other 
triggers. The BAT was positive in only 1 patient, in whom the 
skin test and sIgE were also positive. Compared to patients 
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ue to identify those patients who are sensitized to Hyme-
noptera venom before they experience anaphylaxis, and 
maybe even preemptively treat them with immunothera-
py. Conventional tests including intradermal tests and 
measurement of specific immunoglobulin E (sIgE) in se-
rum are feasible to confirm sensitization after a patient 
has experienced an anaphylactic reaction, but they are not 
currently deemed useful for screening purposes. In par-
ticular, the presence of sIgE does not always predict Hy-
menoptera venom-related allergy (HVA). The basophil 
activation test (BAT) has been proposed as a useful ad-
junct in the diagnosis of allergic disease, especially in pa-
tients with negative or contradictory conventional tests 
 [7–10] . In the BAT, basophils are used as an in vitro mod-
el for mast cells, despite their slightly different character-
istics regarding appearance and function. Both, however, 
contain granules of preformed molecules that can cause 
an anaphylactic reaction after degranulation. Degranula-
tion occurs after a wide range of stimuli, for instance ac-
tivation by IgE, complement mediators, or bacteria-de-
rived peptides  [11] . Using the BAT, both IgE-mediated 
and IgE-independent type 1 hypersensitivity can be mea-
sured in vitro  [12–14] . In previous studies, the BAT has 
been found to have varying diagnostic characteristics 
when compared with intradermal tests and sIgE measure-
ment in populations with, as well as without, mastocyto-
sis  [15, 16] . 
 Subjects and Methods 
 The objective of this study was to determine whether the BAT 
is also applicable for screening SM patients for Hymenoptera ven-
om sensitization and thereby their risk for anaphylaxis due to a 
wasp sting. We used sIgE as a control measurement to determine 
who was sensitized to Hymenoptera venom.
 Subjects 
 From September 2011 to January 2012, we prospectively in-
cluded patients who presented to the outpatient clinic for a routine 
visit and who fulfilled the WHO criteria for SM  [17] . We collected 
both demographic and disease related-data including personal 
characteristics, the subtype of SM, and a detailed history regarding 
anaphylaxis. All patients gave informed consent. We retrospec-
tively checked all patient files until September 2015 (3 years) for 
new episodes of anaphylaxis.
 Basophil Activation Test 
 Venom-activated basophils were identified by flow cytometry 
using the Flow2 CAST system (Bühlmann Laboratories AG, 
Schönenbuch, Switzerland) according to the manufacturer’s in-
structions. Briefly, 50 μl EDTA-anticoagulated whole blood of the 
patient were incubated for 25 min at 37  °  C with 50 μl venom extract 
diluted to 100 ng/ml in the presence of 100 μl stimulation buffer 
containing calcium and IL-3. We used the Hymenoptera venom 
included in the Flow2 CAST kit. Subsequently, 20 μl fluorochrome-
labeled monoclonal anti-CD63 antibodies and anti-CCR3 anti-
bodies (staining reagent) were added (Bühlmann Laboratories). 
After washing the samples, flow cytometry was performed using a 
FACSCalibur device (BD BioSciences, USA) to detect degranu-
lated CCR3-positive basophils based on the amount of CD63 ex-
pression. We used stimulation buffer as the negative control, and 
the positive control consisted of anti-FcεRI antibodies (all from 
Bühlmann Laboratories). An increase of <15% in CD63-positive 
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 Fig. 1. Flow cytometry plots of a negative BAT ( a ) and a positive 
BAT ( b ), according to the surface CD63 expression on basophils. 
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basophils, compared with the negative control, was considered 
negative. An increase >15% in CD63-positive basophils was con-
sidered a positive result. Results were only considered suitable for 
analysis when the negative and positive controls gave the expected 
results.  Figure 1 shows a flow cytometry plot of patient-derived 
leukocytes indicating CCR3-positive basophils (selected), either 
<15% degranulated (fig. 1a) or >15% degranulated (fig. 1b), based 
on CD63 expression.
 Specific IgE Measurement 
 sIgE antibodies against bee venom (i1) and wasp venom (i3) 
were determined using the Phadia 250 system (Thermo Fisher 
 Scientific/Phadia B.V., Freiburg, Germany). Values of sIgE below 
0.35 kU/l were considered negative. All analyses were performed 
according to the manufacturer’s instructions.
 Statistical Analysis 
 SPSS 21 (IBM SPSS Inc., USA) was used for all statistical anal-
yses. Values are reported as medians with a range or medians with 
a standard deviation (SD). We used χ 2 and t tests to compare dif-
ferent subgroups. However, because of the small population, we 
only performed statistical analysis on relevant characteristics. 
 Results 
 We included 29 patients ( table 1 ). The median age was 
48 years (range 25–72), and 17 patients were female 
(59%). None of the patients were using systemic cortico-
steroids at the time of our study. Patients with a history 
of anaphylaxis had a lower median serum tryptase level 
(p = 0.438) than patients without anaphylaxis, although 
this did not reach statistical significance. Of the 13 pa-
tients who experienced at least 1 anaphylactic reaction,
9 patients reported a wasp sting as the trigger. Three
patients had food-related anaphylaxis after ingestion of 
prawns, hazelnuts, or peanuts, respectively. In 1 patient, 
the trigger for anaphylaxis was unidentified. 
 Appropriate skin tests were performed in all patients 
with reported anaphylaxis after a wasp sting. In 2 of these 
9 patients, skin tests were negative. These patients also 
had undetectable sIgE for either wasp or bee venom.
 Table 1.  Patient characteristics (n = 29)
No history of
anaphylaxis (n = 16)
History of anaphylaxis not
Hymenoptera-related (n = 4)
Hymenoptera-related
anaphylaxis (n = 9)
Age at diagnosis, years 44 (25 – 56) 50 (38 – 63) 52.5 (36 – 72)
Females 9/16 4/4 4/9
Time anaphylaxis to BAT, years N/A 2 (0.5 – 6) 3 (2 – 10)
Wasp sting after the diagnosis 0/14 0/4 0/8
Wasp immunotherapy before the BAT N/A 0/4 1/9
Subtype of SM
ISM 14/16 4/4 9/9
ISMs+ 12/14 2/2 5/9
ISMs– 2/14 2/2 4/9
ASM 2/2 0/0 0/0
WHO criteriaa
Skin lesions 14/16 2/4 5/9
Bone marrow histology positive 5/6b 1/1 3/3
Bone marrow morphology positive 10/10 2/2 8/8
Tryptase at diagnosis, ng/l 38.7 (9.8 – 324.0) 31 (22.6 – 44.1) 23.7 (15.9 – 160)
D816V mutation detected 6/8 2/3 6/6
CD2 or CD25 detected 8/8 2/2 6/6
Conventional allergy tests
Intradermal tests for wasp positivity N/A 0/4 7/9
Specific IgE to Hymenoptera venom 0/16 1/4 6/9
Specific IgE levels, kU/l – 0.29 0.60 (0.22 – 4.61)
Specific IgE to bee venom 0/16 0/16 1/9
 Values are presented as numbers/total or medians (range) unless otherwise stated. ASM = Aggressive systemic mastocytosis; N/A = 
not applicable. a Some data are missing because the initial workup for SM was performed at other medical centers. b One patient had a 
negative bone marrow biopsy for SM but fulfilled all 3 minor WHO criteria for SM.
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 Of the 9 patients who reported Hymenoptera-related 
anaphylaxis, 5 had detectable sIgE levels for Hymenop-
tera venom. One of these patients had detectable sIgE for 
bee venom, without a clinical history of bee-venom re-
lated anaphylaxis. Skin testing in this patient was positive 
for wasp venom, but negative for bee venom, and thus the 
sIgE for bee venom probably represents irrelevant cross-
reactivity with sIgE for wasp venom. Interestingly, 1 
 patient who reported anaphylaxis due to medication or 
prawns also had detectable sIgE for Hymenoptera venom. 
 All BAT were considered suitable for analysis. Among 
the 29 patients, the BAT was positive in only 1 patient. 
This patient had indolent SM (ISM) without skin lesions 
and had experienced wasp-related anaphylaxis 2 years be-
fore inclusion in our study. Of note, she also had the high-
est level of sIgE to Hymenoptera venom in our popula-
tion (4.61 kU/l) and a positive intradermal test for wasp 
venom. sIgE for bee venom was not detectable in this pa-
tient. In the 3-year follow-up period, 1 patient was lost to 
follow-up. Of the other 28 patients, no one reported an-
other wasp sting, and no one experienced a new episode 
of anaphylaxis. 
 Lastly, data were viewed from a different perspective 
for additional information. Irrespectively of their clinical 
history of anaphylaxis, patients with ISM were further di-
vided into patients with or without skin lesions (ISMs+ 
vs. ISMs–, respectively). Anaphylaxis was significantly 
more frequent in ISMs– versus ISMs+ patients (6/7 vs. 
7/20, p = 0.021). In accordance with this, sIgE to Hy-
menoptera venom also was significantly more often de-
tectable in ISMs– versus ISMs+ patients (5/7 vs. 2/20, 
p = 0.001).
 Discussion 
 We studied the feasibility of the BAT as a screening 
tool for Hymenoptera sensitization in patients with SM. 
Of all of the patients, only 1 had a positive BAT and this 
patient also tested positive for the conventional allergy 
tests (sIgE and skin test). However, 8 other patients with 
a clinical history of HVA, 5 of whom also had demon-
strable sIgE to Hymenoptera and 6 of whom had positive 
intradermal tests, tested negative with the BAT. These 
tests thus did not correlate well in our population, nor did 
the BAT add useful information to the standard combina-
tion of clinical history, sIgE, and skin tests. In addition to 
new data about the BAT, our study provides additional 
evidence on the difference between ISMs+ and ISMs– pa-
tients. It has become increasingly clear in recent research 
that these two subtypes of ISM have entirely different 
clinical phenotypes [ 6 , unpubl. data]. Our results confirm 
that anaphylaxis is more common in ISMs– patients ver-
sus ISMs+. 
 The role and usefulness of the BAT remains a topic of 
discussion in the current literature, with earlier studies re-
porting conflicting evidence. Bidad et al.  [16] studied the 
role of the BAT in the diagnosis and monitoring of HVA 
in SM patients. They found a sensitivity of 87% and a spec-
ificity of 100% in their population. However, all patients 
with HVA also had a positive intradermal test, rendering 
the addition of the BAT redundant. Moreover, the sIgE 
level was significantly higher in this group compared to 
our population. We would therefore postulate that the 
BAT does not add useful information to the conventional 
diagnostic tests for HVA. This hypothesis is supported by 
the results of Bonadonna et al.  [18] . They investigated the 
role of the BAT in SM patients with or without a reported 
reaction to Hymenoptera stings but all without demon-
strable sIgE. In this population, BAT results were all neg-
ative and performing a BAT on top of sIgE and intrader-
mal tests did not contribute to the diagnosis of HVA. Fur-
thermore, Gonzalez-de-Olano et al.  [19] investigated the 
BAT in patients with HVA and SM compared to patients 
with HVA but no SM. Specific IgE was detected in 15 of 
22 SM patients, 9 of whom had a positive BAT result. Of 
the 7 SM patients without sIgE, 3 had a positive BAT. Us-
ing extracts of different wasp and bee species, they even 
found the culprit insect in 2 of these sIgE-negative pa-
tients. Another study by Eberlein-König et al.  [8] also con-
cluded that they were able to identify the culprit insect via 
the BAT in a few complicated cases in which intradermal 
tests and sIgE measurement could not lead to a diagnosis.
 In addition to the different populations studied, an ex-
planation for the strikingly different outcomes in all of 
these studies can be found in technical differences. The 
BAT has not been standardized completely yet, and dif-
ferent laboratories use different techniques. For instance, 
some laboratories use purified cells in their analyses, 
which can increase the sensitivity of the BAT  [20] . Cut-off 
values and incubation substances also vary. Moreover, 
when working with basophils, one has to realize that ba-
sophils differ from (neoplastic) mast cells in certain ways, 
mainly in terms of non-IgE-mediated activation  [21] . The 
main limitations of this specific study are the small num-
ber of patients investigated and the heterogeneity within 
our population. However, we chose this method on pur-
pose to resemble daily practice. Moreover, the main aim 
was to investigate the role of the BAT as a screening meth-
od rather than to confirm the presence of an allergy that 
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had already been confirmed by either clinical anaphylax-
is or conventional tests. Therefore, we also included pa-
tients without a history of anaphylaxis, which leads to a 
lower a priori incidence of HVA and thereby a lower sen-
sitivity of the BAT in this group.
 Lastly, 2 patients with HVA had received immuno-
therapy several years before this study, which could obvi-
ously have influenced the results of the BAT, since this 
is expected to become negative after immunotherapy. 
One of those patients, however, experienced an episode 
of wasp-related anaphylaxis after immunotherapy and 
therefore the effect of immunotherapy apparently was 
negligible.
 Conclusions 
 Considering our results in relation to previous studies, 
we prudently conclude that the BAT is not a useful test to 
screen random SM patients for their risk of HVA. Fur-
thermore, by combining the patient’s clinical history, in-
tradermal testing, and sIgE measurement, a diagnosis of 
HVA can be confirmed or declined in most patients. The 
BAT may be of additional use in very complicated pa-
tients with conflicting results of conventional tests, but 
we could not confirm this in our study. More systematic 
research in a carefully selected population might provide 
more insight in the role of the BAT in this niche.
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